About FDA
Percent of OSEL inter-Office eConsults completed on time during the month
Dictionary: CDRH uses the internal expert consultation process to acquire information and analysis on issues related to medical devices. eConsult is the system CDRH uses to manage and monitor expert consult requests. Inter-office consultations are completed for a variety of work products requiring expertise across CDRH offices, including premarket device submissions, post-approval studies, and compliance and enforcement actions.
Fiscal Year - 2010
Time | Target | Percent |
---|---|---|
Oct 2009 | 75 | 83 |
Nov 2009 | 75 | 88 |
Dec 2009 | 75 | 74 |
Jan 2010 | 75 | 87 |
Feb 2010 | 75 | 73 |
Mar 2010 | 75 | 85 |
Apr 2010 | 75 | 80 |
May 2010 | 75 | 75 |
Jun 2010 | 75 | 93 |
Jul 2010 | 75 | 94 |
Aug 2010 | 75 | 94 |
Sep 2010 | 75 | 93 |
FY 2010 Overall: 86%
Number of OSEL inter-Office eConsults completed on time during the month
Fiscal Year - 2010
Time | Target | Number |
---|---|---|
Oct 2009 | N/A | 75 |
Nov 2009 | N/A | 86 |
Dec 2009 | N/A | 73 |
Jan 2010 | N/A | 87 |
Feb 2010 | N/A | 74 |
Mar 2010 | N/A | 129 |
Apr 2010 | N/A | 98 |
May 2010 | N/A | 90 |
Jun 2010 | N/A | 164 |
Jul 2010 | N/A | 118 |
Aug 2010 | N/A | 181 |
Sep 2010 | N/A | 124 |
FY 2010 Total: 1,299
Total number of OSEL inter-Office eConsults completed during the month
Fiscal Year - 2010
Time | Target | Number |
---|---|---|
Oct 2009 | N/A | 90 |
Nov 2009 | N/A | 98 |
Dec 2009 | N/A | 99 |
Jan 2010 | N/A | 100 |
Feb 2010 | N/A | 101 |
Mar 2010 | N/A | 152 |
Apr 2010 | N/A | 122 |
May 2010 | N/A | 120 |
Jun 2010 | N/A | 177 |
Jul 2010 | N/A | 126 |
Aug 2010 | N/A | 193 |
Sep 2010 | N/A | 133 |
FY 2010 Total: 1,511
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.